Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 957 participants.
Also called NCT05359068
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 957 participants
- Registry
-
NCT05359068
-
- Other papers using this trial's data
- Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05359068. Randomized; double masking; primary purpose treatment. Start 2021-06-10 (actual); primary completion 2023-12-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- SPH3127 tablet
- Intervention (Drug)
- SPH3127 tablet
- Intervention (Drug)
- SPH3127 tablet
- Intervention (Drug)
- Valsartan
- Intervention (Drug)
- SPH3127 tablet
- Intervention (Drug)
- Valsartan
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Record details
- Record id
cardio:ct-nct05359068- Content hash
291e3c74cd6528de31c97f01156edbf4d646b5586ee05e6ba8568ec73848121f